We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

RBC Capital cuts Dr Martens target price

Wed 27 March 2024 07:13 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - RBC Capital Markets cut its price target on Dr Martens on Wednesday to 85p from 100p as it lowered its estimates for FY24-26 earnings per share by 7% to 10%.

The bank said Dr Martens should be able to deliver on materially lower guided and consensus expectations for FY24, due 30 May.

The bank said Spring/Summer shipment timings could be a swing factor, however it believes Q4 DTC trends will be an important data point as well as FY25.

RBC said it expects the company's FY25 guidance to strike a "cautious tone". It expects revenue guidance of 'mid-single digit' and an EBITDA guidance range of £200m to £210m, which implies mid-high single-digit growth year-on-year.

RBC rates the shares at 'sector perform'.

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.